Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS107 in advanced pancreatic cancer
NCT05657418Phase 1Terminated
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Mar 2022
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of JS107 in pancreatic cancer (PC) (2 arms), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoints: Maximum Tolerated Dose at 12 months and Recommended Phase 2 Dose at 24 months. Started Mar 2022; status: terminated.
02
Drugs
JS107
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05657418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05657418.